Nanoform Finland Oyj (NANOFH) Earnings Call Transcripts

Nanoform Finland Oyj's Latest Earnings Call - Q1 FY2026

In the first quarter of fiscal year 2026, Nanoform Finland Oyj reported record revenue and gross margin, signaling strong operational momentum. Revenue exceeded EUR 1.5 million, marking a 45% growth over the past six years, while gross margin reached a record 94%. Management reiterated their cash burn target for 2026 to be below EUR 10 million, supported by a significant reduction in operating costs by 31% year-over-year. The company also announced its first exclusivity agreement in the biologics space, which is expected to enhance future revenue streams and market positioning.

Reported metrics

Guidance from management

Management maintained their cash burn target for 2026 to be below EUR 10 million and reiterated their growth targets, aiming for above 50% CAGR from 2025 to 2030.

What management said

So Christian, thanks for the question, and there are 2 parts to it. One is the reasons for why they went with us. If I give a sort of slightly tongue-in-the-cheek answer, it's because they liked what we had to offer. I'm sure Peter will give you a little bit more details. Then about the next steps, this is really about now together making sure that we get into clinic with these assets as fast as possible, and that wi...

Maybe I can start and Christian, then if you sort of build upon that. I think the first thing, of course, is the obvious advantages of subcutaneous delivery over IV. And then I think the second thing I would highlight, and as we said last week as well, is the great data they got from advanced preclinical studies with our materials. So I think that's really sort of the key things. But Christian, maybe you want to give...

What analysts pressed on

Analysts expressed concerns regarding the pace of GMP capabilities development for the biologics platform and the potential need for incremental investments to support growing interest in exclusivity deals. There were questions about the timeline for achieving GMP status and how funding will be managed without significant CapEx.

Main topics on the call

• Record Revenue and Gross Margin — Nanoform achieved a record first quarter revenue exceeding EUR 1.5 million, with a gross margin of 94%. CEO Edward Haeggstrom noted, "This shows that we are starting to become more and more involved in getting this into ...
• Exclusivity Agreement in Biologics — The company signed its first exclusivity agreement with a U.S. biopharmaceutical company, which includes a $1 million upfront payment and potential high tens of millions in milestone payments. Christian Jones stated, "Th...
• Reduction in Operating Costs — Operating expenses fell by 31% year-over-year, bringing them to levels not seen in five years. CFO Albert Haeggstrom emphasized, "When you increase your top line and you decrease your cost, the impact on cash flow and EB...
• Cash Burn Target for 2026 — Management reiterated the cash burn target for 2026 to be below EUR 10 million, indicating confidence in operational efficiency. Albert Haeggstrom mentioned, "We are on track for this."

Read the full Nanoform Finland Oyj transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 17 Nanoform Finland Oyj earnings call transcripts on record, spanning February 22, 2022 to May 19, 2026. Based on this history, Nanoform Finland Oyj reports quarterly. The most recent call on file is dated May 19, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

NANOFH

Exchange

HLSE

Country

FI

Sector

Health Care

Industry

Life Sciences Tools and Services

Calls on record

17

First call

February 22, 2022

Most recent

May 19, 2026

Reporting cadence

quarterly